Utilising hybridoma technology two new tumour markers, CA and CA 50, have recently been developed for the diagnosis of digestive tract malignancies. The antibodies used in these tests have been obtained by immunising mice with two different human colorectal carcinoma cell lines (Koprowski et al., 1979; Lindholm et al., 1983) . The antigenic determinant of CA 19-9 is sialylated Lewisa-blood group substance (sialosyl-fucosyl-lactotetraose) and that of CA 50, both the former structure, and also sialosyl-lactotetraose, which lacks the fucosyl residue of the sialylated Lewisa-antigen . Both epitopes are expressed on cell surfaces as glycolipids and glycoproteins. In patients with digestive tract malignancies, the antigens are also found in serum where they are associated with a high molecular weight carbohydrate rich mucin fraction Lindholm et al., 1983) .
The highest frequency of elevated serum CA 19-9 and CA 50 levels are found in samples from patients with pancreatic cancer, 71-92% of whom are reported to have elevated marker values (DelVillano et al., 1983; Schmiegel et al., 1985; Habib et al., 1986; Haglund et al., 1986; Steinberg et al., 1986; Blind et al., 1987; Haglund et al., 1987; Kuusela et al., 1987) . High proportions of increased concentrations are also found in patients with colorectal and biliary tract cancers Kuusela et al., 1984; Bruhn et al., 1985; Paganuzzi et al., 1985; Kuusela et al., 1987) . The drawback of both tests are the findings that clearly elevated levels mainly are found in patients with advanced disease, which can rather easily be diagnosed also by other clinical and laboratory criteria. In these patients the possibilities for a curative operation are usually rather poor. Falsely positive test findings due to benign biliary tract obstruction hamper a correct evaluation of the assay results in jaundiced patients Haglund et al., 1986; Haglund et al., 1987) .
Carcinoembryonic antigen (CEA) is a 180 kd molecular weight glycoprotein expressed in embryonic colonic mucosa and in carcinomas of the gastrointestinal tract (Gold & Freedman, 1965) . Being one of the most extensively studied tumour marker it has a well established use in monitoring cancer patients.
CA 242 is a new tumour marker defined by the monoclonal antibody C-242 which was obtained by immunising mice with a human colorectal carcinoma cell line COLO 205 . The structure of the CA 242 antigen is still unresolved, but there is evidence that it is of carbohydrate nature related to type I chain, but different from that of CA 19-9 and CA 50 (O. Nilsson, personal communication) . In serum, the CA 242 epitope seems to be located on the same macromolecular complex as CA 19-9 and CA 50. This has made it possible to set up a solid-phase immunoassay, in which antibodies against CA 50 and CA 242 are used as 'catcher' and 'detector' antibodies, respectively (Nilsson et al., 1988) .
The aim of the present investigation was to study the CA 242 levels in sera from patients with various digestive tract malignancies. Special attention was devoted to the comparison of the CA 242 concentrations with those of CA 19-9, CA 50 and CEA. 
CA 242 in gastric diseases
The CA 242 level was elevated in 12 out of 27 patients with gastric cancer (44%; median 13 U ml-'; range: 3-2610 U ml-'), whereas benign gastric diseases were associated with an increased concentration in three out of 43 patients (7%; median 3 U ml'; range: 3-125 U ml') (Table I; Figure 1 ).
Six out of 27 patients with gastric cancer (22%) had a value higher than any patient with benign gastric diseases. (Table  II) . A poor overall correlation was found between CA 242 and CEA (Table II) , with the exception of gastric diseases, in which a correlation coefficient of 0.89 was found.
In Table I , CA 242 is compared with CA 19-9, CA 50 and CEA using the recommended cut-off values for each marker. For comparison of these markers at the same specificity level, cut-off limits for each marker representing the mean + 2 s.d. of values found in relevant benign diseases were determined (Table III) . Colorectal diseases Using the recommended cut-off levels, CA 242 and CEA had similar sensitivities (55% and 57%, respectively) and specificities (90% and 83%, respectively) for colorectal cancer (Table I ). The sensitivities of CA 19-9 (34%) and CA 50 (40%) were lower, but the specificities higher (100% and 97%, respectively) ( Gastric diseases In gastric diseases, all markers had a similar sensitivity (41-52%) using the recommended cut-off values. However, CA 19-9 had the highest specificity (Table  I) . Therefore, using cut-off levels based on benign diseases, CA 19-9 was positive in 67% of patients with gastric cancer, whereas other assays showed an elevated marker level in only 30-37% of the patients (Table III) .
Liver diseases CA 50 and CEA were elevated in about half of the patients with liver cancer, whereas only one of 11 patients had an elevated CA 19-9 value, and none of the patients had a CA 242 value above the recommended cut-off level (Table I) . However, CA 50 and CEA were elevated also in many patients with benign liver diseases (44% and 17%, respectively) ( Table I) .
Using the cut-off levels based on benign liver diseases, all new tests showed very low sensitivities (0-9%) for liver cancer. CEA was elevated in 27% of these patients (Table  III) .
Pancreatic and biliary diseases The sensitivities of all marker tests for pancreatic and biliary cancer were higher than for other digestive tract carcinomas (59-76%) ( Table I) . CA 19-9 and CA 50 had slightly higher sensitivities than CA 242, but CA 242 had a higher specificity than the other markers (Table I) .
Using cut-off levels based on benign pancreatic and biliary diseases, CA 242 and CA 19-9 had clearly higher sensitivities (68% and 61%, respectively) than CA 50 and CEA (46% and 17%, respectively) ( Table III) .
Discussion
CA 242 was elevated in a high percentage of sera from patients with colorectal, pancreatic and biliary tract cancers. This could be expected considering that the serum levels of this new tumour correlated well with those of CA 19-9 and CA 50, which both are well documented markers for digestive tract malignancies (DelVillano et al., 1983; Holmgren et al., 1984; Jalanko et al., 1984; Kuusela et al., 1984; Bruhn et al., 1985; Chan et al., 1985; Paganuzzi et al., 1985; Haglund et al., 1986; Haglund et al., 1987; Kuusela et al., 1987 (Carr-Locke, 1980; Haglund et al., 1986 Haglund et al., , 1987 and in patients with benign liver diseases, which frequently cause elevation of CA 50 and CEA (Haglund et al., 1986 .
When reporting results of tumour markers, the use of cut-off values recommended by the manufacturers makes it possible to compare the figures with those of other laboratories. However, there always are differences in patient materials, and the cut-off levels of various markers may be settled in different ways. Therefore, when comparing different tumour markers, it is essential to measure the serum concentrations of the same patient material and to compare the sensitivities at a fixed specificity level. In this study, we set the cut-off values for each type of cancer as the mean plus two standard deviations of the marker levels found in patients with relevant benign diseases.
Elevated values in a part of the patients with benign diseases usually cause an increase of the cut-off levels compared with those based on healthy blood donors, i.e. the recommended cut-off levels. However, in benign colorectal and gastric diseases the mean + 2 s.d. levels for CA 19-9 are lower (21 U ml' and 12 U ml', respectively) than the recommended cut-off level of 37 U ml. The same is true for CA 50 in colorectal diseases. Interestingly, the mean + 2 s.d. level for CA 242 in benign pancreatic and biliary diseases is similar to the recommended upper limit of normal, whereas contrarily the cut-off levels of CA 19-9, CA 50 and CEA markedly increase, especially in patients with extrahepatic cholestasis.
Using the recommended cut-off levels, CA 242 detected more Dukes A and B carcinomas than CEA (47% vs 32%), whereas CEA more often was elevated in advanced carcinomas. An elevated level of both or either of the markers increased the sensitivity to 72% (from 55% and 57%, respectively) with a decrease of the specificity from 90% and 83% for CA 242 and CEA, respectively, to 79%. The combination of the two markers will thus gain 15-17% in primary diagnosis of colorectal cancer, with a loose of 4-11 % in specificity.
Using cut-off levels based on benign colorectal diseases, the new markers were more sensitive than CEA in detecting primary localised colorectal cancers. CA 50, CA 19-9 and CA 242 detected 7 (44%), 6 (38%) and 5 (31%), respectively, out of 16 Dukes A or B colorectal cancer patients, who had normal CEA levels. An elevation of CEA never occurred without a concomitant elevation of the other markers. In primary Dukes C and D colorectal carcinomas and in patients with recurrencies of colorectal cancer there was no significant difference between the markers.
Pancreatic and extrahepatic biliary cancer mostly cause similar clinical signs and symptoms, and both benign pancreatic diseases and benign and malignant obstruction of the bile duct may be differential diagnostic problems in the diagnosis of pancreatic cancer. Therefore, in this study these diseases are evaluated together.
In pancreatic and biliary diseases the sensitivity of CA 242 was somewhat lower (68%) than that of CA 19-9 (76%) and CA 50 (73%), but the specificity was clearly higher. Elevated CA 19-9 and CA 50 values are frequently seen in benign pancreatic diseases, and especially in patients with extrahepatic cholestasis Haglund et al., 1986 Haglund et al., , 1987 . In these patients CA 242 is rarely elevated. Determining the threshold levels on the basis of benign diseases caused a marked elevation of cut-off values for CA 19-9 and CA 50 (155 U ml-' and 145 U ml-', respectively), whereas the cut-off value for CA 242 remains as low as 20 U mlV '. This indicated that CA 242 might be more effective in detecting pancreatic and biliary tract cancer. The sensitivities of CA 19-9 and CA 50 fall to 61% and 46%, respectively, whereas that of CA 242 remained unchanged (68%). A more marked decrease of the sensitivities of CA 19-9 and CA 50 might have been expected. One explanation might be the fact that patients included in this study mainly had disseminated pancreatic or biliary tract cancer associated with very high serum concentrations well above the cut-off levels. CEA has a lower sensitivity and specificity than the other markers in these diseases.
Our The results of this study show that the expression of CA 242 is rather similar to the previously reported tumour markers, CA 19-9 and CA 50. The lower frequency of elevated values in benign diseases, especially in patients with jaundice, compared with CA 19-9 and CA 50, is a clear advantage. Evaluation of larger patient materials and studies on the utility of CA 242 in the follow-up of operated patients with pancreatic cancer, are needed to show a possible clinical advantage of CA 242. The sensitivity of the CA 242 test for gastric carcinoma is too low to be clinically useful. The sensitivity for localised colorectal carcinoma is also low, only 47%, but still higher than that of CEA. However, the benefit in this material of combining CEA and CA 242 encourages further studies also in this group of cancer patients. In this material 54% on the patients with recurrence of colorectal carcinoma had an elevated CA 242 serum level at the time of verification of the recurrence. Clinically it would, however, be of importance to know whether the marker level elevates prior to clinical signs and symptoms of recurrence, thus providing a lead time compared to conventional diagnostic methods. A follow-up study with CA 242 in patients with colorectal carcinoma is now in progress. As a conclusion, CA 242 is a promising new tumour marker and may have a place in clinical diagnosis of digestive tract malignancies.
